Paul Walker Net Worth

The estimated Net Worth of Paul Edward Walker is at least $31.2 Million dollars as of 17 July 2023. Mr. Walker owns over 333,333 units of Allakos Inc stock worth over $14,927,471 and over the last 9 years he sold ALLK stock worth over $15,831,688. In addition, he makes $431,760 as Independent Director at Allakos Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Walker ALLK stock SEC Form 4 insiders trading

Paul has made over 16 trades of the Allakos Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 333,333 units of ALLK stock worth $999,999 on 17 July 2023.

The largest trade he's ever made was selling 10,376,936 units of Allakos Inc stock on 24 May 2022 worth over $726,386. On average, Paul trades about 1,011,185 units every 39 days since 2015. As of 17 July 2023 he still owns at least 24,471,264 units of Allakos Inc stock.

You can see the complete history of Mr. Walker stock trades at the bottom of the page.

Paul Walker biography

Paul Edward Walker serves as Independent Director of the Company. Mr. Walker was a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, from April 2008 to August, 2018, and has been a General Partner since September, 2018, where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008, Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, private-investment-in-public-equity and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000, Mr. Walker served as a portfolio manager at Franklin Resources, a global investment management organization known as Franklin Templeton Investments. Mr. Walker previously served as a member of the board of directors of TESARO, currently serves as a member of the board of directors of TRACON Pharmaceuticals, Trillium Therapeutics, is a board observer of Sunesis Pharmaceuticals and manages a number of NEA’s other latestage and public investments. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the designation of Chartered Financial Analyst.

What is the salary of Paul Walker?

As the Independent Director of Allakos Inc, the total compensation of Paul Walker at Allakos Inc is $431,760. There are 12 executives at Allakos Inc getting paid more, with Robert Alexander having the highest compensation of $12,559,300.

How old is Paul Walker?

Paul Walker is 45, he's been the Independent Director of Allakos Inc since 2017. There are 10 older and no younger executives at Allakos Inc. The oldest executive at Allakos Inc is Steven James, 62, who is the Independent Director.

What's Paul Walker's mailing address?

Paul's mailing address filed with the SEC is 2855 SAND HILL ROAD, , MENLO PARK, CA, 94025.

Insiders trading at Allakos Inc

Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red..., and Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.

What does Allakos Inc do?

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

Complete history of Mr. Walker stock trades at Genocea Biosciences Inc, Regulus Therapeutics Inc, Savara Inc, TRACON Pharmaceuticals Inc, Trillium Therapeutics Inc, Allakos Inc, Mirum Pharmaceuticals Inc, Trevi Therapeutics, Marker Therapeutics, Akouos, Metacrine, and Bright Health

Allakos Inc executives and stock owners

Allakos Inc executives and other stock owners filed with the SEC include:

• Robert Alexander,
  Chief Executive Officer, Director
• Adam Tomasi,
  President, Chief Operating Officer
• Henrik Rasmussen,
  Chief Medical Officer
• Leo Redmond,
  Chief Financial Officer
• Mark Asbury,
  Chief Legal Officer and General Counsel
• Dr. Robert Alexander Ph.D.,
  CEO & Director
• Dr. Adam L. Tomasi Ph.D.,
  Pres & COO
• Dr. Henrik Sandvad Rasmussen,
  Strategic Advisor
• Mark Asbury,
  Chief Legal Officer & Gen. Counsel
• Daniel Janney,
  Independent Chair of the Board
• Robert Andreatta,
  Independent Director
• John McKearn,
  Independent Director
• Paul Walker,
  Independent Director
• Steven James,
  Independent Director
• Dr. Craig Paterson M.D.,
  Chief Medical Officer
• Alan Chang,
  Director of Medical Affairs & Data Analytics
• Tim Varacek,
  Chief Commercial Officer
• Dr. Sally D. Bolmer,
  Sr. VP of Regulatory Affairs & Drug Devel.
• Dr. Ruby Casareno Ph.D.,
  Sr. VP of Technical Operations
• Baird Radford III,
  Chief Financial Officer
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Iii, L.P.River...,
  
• Partners Viii, L.P.Alta Par...,
  
• Neil Murray Hamilton Graham,
  
• Amy L Ladd,
  
• Dolca Thomas,
  
• Partners Next Gen Fund I Ma...,
  
• Peter A Hudson,
  
• Robert J More,
  
• Guy P Nohra,
  10% owner
• Natalie C. Holles,
  Director
• Partners Next Gen Fund I Ma...,
  
• Margaret Nell Fitzgerald,
  General Counsel and Secretary
• Craig A. Paterson,
  Chief Medical Officer
• Everett Rand Sutherland,
  Director
• Partners Management Viii, L...,
  
• Chin Hyok Lee,
  Chief Medical Officer
• Harlan Baird Radford,
  Chief Financial Officer